Quality and performance measurement has become an integral part of the healthcare system. As pharmacists continue to increase their role and exposure as healthcare providers, they are well positioned to assist in identifying ways to improve the quality of care delivered and to play an integral role in the development of quality measures, according to Curtis Collins, PharmD, MS, BCPS (AQ-ID), FASHP, who spoke at the ASHP Midyear Meeting.
Healthcare quality measurement has become an integral part of the healthcare system. Curtis Collins, PharmD, MS, BCPS (AQ-ID), FASHP, told attendees that the National Quality Forum (NQF) is at the forefront of organizations endorsing quality measures. Dr Collins described the history of healthcare quality and safety organizations, which began with the American College of Surgeons setting minimum standards for hospitals in 1917. Quality organizations to follow include the Joint Commission for the accreditation of hospitals, the National Committee for Quality Assurance, the Agency for Healthcare Research and Quality, Leapfrog, several Centers for Medicare & Medicaid Services (CMS) programs, and most recently, the Pharmacy Quality Alliance (PQA).
Hospital value-based purchasing is one area affected by quality measures. According to Dr Collins, more quality indicators are being added each year and the financial penalties are continuing to grow. The 1% reduction in payments to hospitals that do not meet the quality measure requirements will increase to a 2% reduction in 2017.
By virtue of his experiences serving on an NQF committee, Dr Collins offered a unique perspective on the development of quality measures. NQF was established in 1999 as a result of the recommendation of the Advisory Commission on Consumer Protection and Quality in the Health Care Industry, a Bill Clinton initiative. The department of Health and Human Services relies on NQF-endorsed measures through programs such as the CMS Physician Quality Reporting System and the Electronic Health Records (EHRs) Incentive Program. The board of directors consists of 31 voting members; however, in 2012, more than 800 experts across the country took part in measure review, measure selection, and priority setting committees. NQF’s vision includes being the primary go-to organization for quality and efficiency initiatives, and being an important motivating force for and facilitator of continuous quality improvement.
According to NQF, a performance measure is a way to calculate whether and how often the healthcare system is doing what it should. The performance measures developed by NQF fall into 3 categories—structural, process, and outcomes. Most measures are either process or outcomes measures. Dr Collins provided examples of measures that were submitted to the NQF. To illustrate the lifecycle of a performance measure, Dr Collins discussed a measure developed in Minnesota that evaluates depression remission at 6 months. First, depression prevalence was determined. Then, an assessment tool was developed, a local initiative was performed, and the results from that initiative encouraged changes in practice. Results were made public, and NQF endorsed the measure as a national consensus standard. The tool was tweaked for use in an EHR, and the measure was suggested for inclusion in CMS’ Meaningful Use health information technology payment program by an NQF-convened group. Another example provided was a measure related to the number of babies electively delivered prior to 39 weeks. The measure was developed by Hospital Corporation of America, endorsed by NQF, and then adopted by the Joint Commission, which led to $1 billion in savings and 500,000 fewer neonatal intensive care unit days.
In 2011, there were 917 endorsed quality measures. Of those, cardiovascular-related measures make up the majority. NQF has a call for measures, and various organizations submit quality measures for review. Each measure is broken down into a therapeutic area for review. NQF approached ASHP and various pharmacy organizations requesting pharmacist involvement on NQF committees. There is an appeal process if a measure is not approved. Approved measures are subject to annual maintenance updates and endorsement reviews on a 3-year cycle.
Measures are evaluated based on 4 major and 5 minor criteria. Each criterion is voted on separately and can be categorized via a rating scale as met completely, partially, minimally, not at all, or as not applicable. One criterion that requires a yes vote assesses the importance of the measure. In other words, is there an underserved population this measure will help, and are there gaps in care? Additional criteria include assessments of:
The PQA is working on pharmacy measurement development, and ASHP’s current president serves on the PQA board. An ASHP staff member convened 20 to 30 pharmacists to identify therapeutic areas that pharmacy could endorse. This group identified 4 areas (anticoagulants, pain management, glycemic control, and antibiotic stewardship). With ASHP’s sponsorship of the Pharmacy Practice Model Initiative, Dr Collins noted that pharmacists are in a good position to respond to quality measures and play an integral role in the development of these measures.
NGS-Based Test Accurately Detects Post–Allo-HSCT Relapse in AML, MDS
February 21st 2025The next-generation sequencing (NGS)–based AlloHeme test accurately predicted relapse following allogeneic hematopoietic stem cell transplantation (allo-HSCT) in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
“Expanding Access Isn’t Just About Fairness—It’s About Building Better Treatments for Everyone”
February 16th 2025Regina Barragan-Carrillo, MD, a postdoctoral fellow at City of Hope Comprehensive Cancer Center, discussed findings that show 76% of renal cell carcinoma trials take place in wealthy countries, amid news that clinical trial access for the world's poor may become even more challenging.
Read More
Amid Debate Over Diversity, RCC Trials Still Struggle to Reflect Patient Populations
February 16th 2025Abstracts presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium reflect the ongoing challenge with enrolling diverse patient populations in trials, despite stated goals.
Read More